Antineoplastic Agents, Immunological
Concept
Vocabulary Service
Overview
subject area of
-
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies Conference Paper
-
Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature Academic Article
-
Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety? Academic Article
-
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial Academic Article
-
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma Academic Article
-
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Academic Article
-
Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer Academic Article
-
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis Academic Article
-
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events Academic Article
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Academic Article
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Academic Article
-
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma Academic Article
-
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12* Academic Article
-
Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites Academic Article
-
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP) Academic Article
-
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors Academic Article
-
Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review Academic Article
-
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer Academic Article
-
Immunotherapy in the Elderly Academic Article
-
Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses Academic Article
-
Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab Academic Article
-
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial Academic Article
-
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013 Academic Article
-
Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases Academic Article
-
Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort Academic Article
-
Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis Academic Article
-
Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review Academic Article
-
Targeted therapy for metastatic renal cell carcinoma Academic Article
-
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma Academic Article
-
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Academic Article